Inspect each claim in a paper against the experiments and reported results that support it, including limitations and provenance.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review
Explore by Goal
"A gene is a long sequence of coded letters, like computer information. Modern biology is becoming very much a branch of information technology."
- Richard Dawkins
Quick Explanation
Copied
Core takeaway (skeptical)
Broad-spectrum antibiotics depleted gut bacteria (~10,000-fold drop; lasting diversity loss) without changing influenza vaccine neutralization broadly in trial-1, but did impair H1N1-specific neutralization/IgG1/IgA in trial-2 (low baseline titers), alongside antibiotic-driven pro-inflammatory signaling and large bile-acid perturbations (notably secondary bile acids, including lithocholic acid).
Long Explanation
Paper Review (Systems Immunology): Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans
Evidence used: full text provided by user + the paper DOI as the primary source.
At-a-glance map (what changed β what it correlated with)
1) Intervention
Broad-spectrum oral antibiotics (neomycin + vancomycin + metronidazole) for 5 days, starting 3 days pre-vaccination and continuing to day +1.
2) Direct microbiome disruption
~10,000-fold reduction in gut bacterial load and long-lasting diminution in bacterial diversity; partial compositional recovery still detectable up to ~6 months.
3) Vaccine immune outcome (heterogeneous by baseline immunity)
Trial-1 (broader baseline immunity) largely showed no significant difference in neutralization/seroconversion; Trial-2 (low pre-existing titers) showed impaired H1N1-specific neutralization plus reduced H1N1-specific IgG1 and IgA responses, with altered antibody affinity/binding.
4) Mechanistic signatures
Antibiotics alone induced pro-inflammatory blood signatures (including AP-1/NR4A) and increased dendritic cell activation; metabolomics showed marked bile-acid trajectory changes, especially a ~1,000-fold reduction in secondary bile acids (with lithocholic acid highlighted), correlated with inflammatory module signaling and inflammasome activation.
Figure 1 β Study structure and key comparisons
Cohort sizes come from the provided full text: Phase 1 enrolled 22 (11 antibiotics, 11 control) and Phase 2 enrolled 11 (5 antibiotics, 6 control).
Figure 2 β Antibiotics drive large gut bacterial load contraction
The abstract states a ~10,000-fold reduction in gut bacterial load and long-lasting diminution in diversity; the results describe a 3β4 log reduction in 16S rRNA copies per gram at vaccination day.
Figure 3 β Secondary bile acids strongly decrease after antibiotics
The abstract states a ~1,000-fold reduction in serum secondary bile acids, with lithocholic acid (LCA) highlighted as a key associated species/metabolite and linked to AP-1/NR4A signaling and inflammasome activation.
Figure 4 β Immune outcomes were trial-dependent (baseline immunity matters)
Directionality is extracted from the paper narrative: Phase 1 reports similar MN titers/seroconversion between groups; Phase 2 reports impaired H1N1-specific neutralization and reduced H1N1-specific IgG1/IgA responses with altered affinity/binding.
Figure 5 β Proposed causal chain vs what is actually demonstrated
What the paper shows (directly)
Antibiotics β microbiome disruption: reduced bacterial load and altered diversity/community structure over months.
Antibiotics β metabolite shifts: altered plasma metabolome with decreased serum secondary bile acids (including LCA).
Inflammation/metabolites β immune readouts are associated: network integration and correlational analyses link bile-acid/inflammatory modules and bacterial taxa/clusters to H1N1 IgG1 outcomes in the selected cohort.
What is not fully proven as causality in humans
Whether LCA/secondary bile acids are necessary for the H1N1-specific impairment is not established by direct mechanistic intervention in the human study (the evidence is correlation/association in multi-omics plus the antibiotic perturbation as a whole).
Whether AP-1/NR4A β inflammasome β antibody impairment is mechanistic in humans is also suggested but not directly causal in the human trial (no targeted pathway perturbation is reported for those nodes).
Figure 6 β Systems integration (what nodes were emphasized)
This schematic matches the paperβs described MMRN findings: bacteria-metabolite links dominate; secondary bile acids (LCA) associate with inflammatory/AP-1/NR4A and inflammasome-related signatures; IgG1 associations show less overlap with bile-acid-linked metabolic clusters and include bacterial clusters and fatty-acid metabolism clusters.
Results (what the paper claims) β and skeptical review
1) Internal validity: strength points
Randomized controlled perturbation in humans with multi-omics readouts (microbiome, transcriptomics, metabolomics, immune phenotyping).
Robust microbiome depletion was verified using 16S rRNA copy number and additional luminal surrogate measurements (flagellin and LPS).
Immune assays were cross-validated (e.g., independent lab confirmation via Luminex for IgG1 impairment in Phase 2).
2) Where the evidence is weaker / confounding risks
Trial heterogeneity (baseline immunity selection): Phase 2 was explicitly pre-screened by low baseline MN titers, which is biologically plausible to create different βwindowsβ for microbiome effectsβbut it also means Phase 1 and Phase 2 are not identical experimental contexts.
Small n per arm (5 vs 6 in Phase 2) limits stability of effect estimates and increases susceptibility to outliers (the paper notes compliance issues for some subjects with microbiome trajectories closer to controls).
Association vs mechanism in humans: the MMRN and metabolite/inflammatory correlations support a plausible mechanism, but causality for specific mediators (e.g., LCA) is not directly tested with targeted restoration/neutralization in the human trial.
Antibiotic effects may be non-microbiome mediated: while the study frames changes as microbiome-mediated (and even measures translocation proxies like fecal flagellin/LPS and serum antibodies), antibiotics can have direct physiological effects that could contribute to systemic inflammation or vaccine kinetics.
Figure 7 β Assay coverage (breadth matters in systems vaccinology)
Assay breadth and the specific technique categories summarized above are stated in the paperβs Results/STAR Methods and methods sections in the provided text.
What would most likely disprove / revise the paperβs mechanistic interpretation?
Failure of replication: if independent trials with similar microbiome depletion and vaccine regimens do not reproduce a baseline-dependent H1N1 impairment pattern, the βmicrobiome mediates vaccine responsivenessβ emphasis would weaken.
Mediator isolation contradicts the chain: if specific bile-acid restoration/antagonism experiments in appropriate models do not reproduce immune module changes and H1N1-specific antibody impairment directionality, then LCA/secondary bile acids would be less likely causal mediators (remaining as biomarkers).
Compliance/trajectory confounds: if re-analysis excluding non-compliers or adjusting for microbiome recovery status eliminates the H1N1-specific effect, the observed association may reflect incomplete or inconsistent perturbation.
Author reviews (open for deeper critique)
Feedback:
Updated: March 23, 2026
BGPT Paper Review
Study Novelty
90%
This work stands out because it provides randomized antibiotic perturbation evidence in humans combined with systems vaccinology-style multi-omics integration (microbiome + transcriptomics + metabolomics + functional antibody readouts) to explain vaccination immunogenicity changes.
Scientific Quality
80%
Scientific quality is high due to randomized controlled design, strong microbiome depletion verification, multi-omics breadth, and independent assay validation in Phase 2; however, small sample sizes per arm and the need for human mediator-isolation experiments mean some mechanistic claims remain association-based rather than directly causal.
Study Generality
70%
The study is directly human and vaccine-relevant, but effect directionality is strain-specific (H1N1 in low-titer participants) and antibiotics are a strong perturbation; generalization to other vaccines, ages, or microbiome baselines is therefore not guaranteed from this single paper.
Study Usefulness
90%
For mechanistic immunology, this provides a concrete human perturbation example linking microbiome depletion to inflammation/metabolite shifts and to vaccine antibody outcomes, and supplies data repositories for reanalysis.
Study Reproducibility
80%
Methods appear sufficiently detailed (antibiotic regimen timeline, sampling, and assay categories) and the paper points to repositories (ImmPort/GEO/SRA). Full reproducibility also depends on availability of raw processed outputs and correct reimplementation of multi-omics steps, but the framework is transparent at a high level.
Explanatory Depth
90%
The paper goes beyond βmicrobiome correlates with immunityβ by proposing mechanistic intermediates (secondary bile acids, AP-1/NR4A inflammatory programs, inflammasome signaling) and separating (i) inflammation linked to bile acids from (ii) antibody-linked bacterial/fatty-acid metabolic clusters via MMRN.
It will download ImmPort SDY1086 plus GEO GSE120719 and SRA PRJNA505336, then reconstruct key timepoint features, re-run modular enrichment, and plot immuneβbile-acid association diagnostics across phases.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
If subsequent trials show that restoring secondary bile acids corrects H1N1 IgG1 impairment without changing AP-1/NR4A inflammatory modules, then the paperβs current inflammatory-mediator emphasis from bile acids would be disfavored.
If reanalysis finds that the H1N1-specific IgG1 effect vanishes after stricter correction for microbiome compliance/trajectory distance, then the causal attribution to microbiome-mediated mediators would weaken substantially.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion